DNMT1 and lymphoid neoplasm: In any case, if DNMT inhibitors do base their therapeutic effect on demethylation of hypermethylated genes, then HNs with higher levels of DNA hypermethylation, like germinal center B-cell lymphomas and precursor lymphoid neoplasms, might theoretically be better targets for such drugs.